Analyst Ratings For G1 Therapeutics (NASDAQ:GTHX)
Today, BTIG Research reiterated its Buy rating on G1 Therapeutics (NASDAQ:GTHX) with a price target of $48.00.
Some recent analyst ratings include
- 3/7/2018-BTIG Research Reiterated Rating of Buy.
- 3/5/2018-Cowen Reiterated Rating of Buy.
- 6/12/2017-Wedbush initiated coverage with a Outperform rating.
- 6/12/2017-Needham & Company LLC initiated coverage with a Buy rating.
- On 3/5/2018 Jennifer K Moses, VP, sold 750 with an average share price of $26.55 per share and the total transaction amounting to $19,912.50.
- On 2/15/2018 Rajesh Malik, Insider, sold 3,776 with an average share price of $20.00 per share and the total transaction amounting to $75,520.00.
- On 2/5/2018 Jennifer K Moses, VP, sold 750 with an average share price of $22.99 per share and the total transaction amounting to $17,242.50.
- On 1/16/2018 Rajesh Malik, Insider, sold 3,776 with an average share price of $22.96 per share and the total transaction amounting to $86,696.96.
- On 1/5/2018 Jennifer K Moses, VP, sold 750 with an average share price of $19.96 per share and the total transaction amounting to $14,970.00.
- On 12/18/2017 Mark A Velleca, Insider, sold 7,500 with an average share price of $20.01 per share and the total transaction amounting to $150,075.00.
- On 12/15/2017 Medimmune Ventures, Inc., Major Shareholder, sold 200,000 with an average share price of $19.75 per share and the total transaction amounting to $3,950,000.00.
Recent Trading Activity for G1 Therapeutics (NASDAQ:GTHX)
Shares of G1 Therapeutics closed the previous trading session at 27.94 up +1.52 5.75% with 26.399999618530273 shares trading hands.